08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

2MD: Phase IIb data

A double-blind, U.S. Phase IIb trial in 62 CKD patients receiving hemodialysis showed that thrice-weekly 220-770 ng oral DP001 for 12 weeks led to a 46% reduction in PTH levels vs. a 31% increase for...
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

DP001: Phase II started

Deltanoid started a U.S. Phase II trial in postmenopausal women. Deltanoid Pharmaceuticals Inc., Madison, Wis.   Product: DP001, 2MD   Business: Autoimmune   Molecular target: NA   Description: Vitamin D analog   Indication: Treat osteoarthritis (OA)   Endpoint: NA...
08:00 , Jan 20, 2003 |  BC Week In Review  |  Company News

Deltanoid, Pfizer deal

Deltanoid granted PFE an option to acquire development and marketing rights to its 2MD, an analog of vitamin D, to treat osteoporosis. PFE also would receive rights to certain other Deltanoid vitamin D analogs....
08:00 , Jan 20, 2003 |  BioCentury  |  Product Development

Deltanoid: Curiously strong

Deltanoid: Curiously strong Osteoporosis represents a large market with room for improvement. All but one of the marketed drugs for the disease slow or stop bone loss, but do not promote new bone formation. Thus,...
07:00 , Oct 7, 2002 |  BC Week In Review  |  Company News

Deltanoid Inc. other research news

Researchers published in the Proceedings of the National Academy of Sciences that 2MD at concentrations as low as 10 -12 M caused primary cultures of osteoblasts to produce bone. 2MD caused a 9% increase in...